myeloMATCH Treatment Trials
|
MyeloMATCH is a group of clinical trials for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). These trials test new precision medicine treatments for patients with myeloid cancers, from diagnosis through multiple stages of their treatment journey. |
myeloMATCH Links
|
The myeloMATCH trial's screening protocol opened in May 2024.
New myeloMATCH treatment trials (sub-studies) will be opened regularly. The treatment trials below are now open and enrolling.
- MM1OA-EA02, led by the ECOG-ACRIN Cancer Research Group:
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
- MM1YA-CTG01 (AL6), led by the Canadian Cancer Trials Group:
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
- MM1YA-S01, led by the SWOG Cancer Research Network:
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial